Genetics in Neonatology: What You Should Know in 2022

Golder N Wilson MD PhD, Clinical professor of pediatrics, TTUHSC Lubbock No conflicts to declare

Following this session, the participant should be able to:

Describe the types of DNA testing

Recommend appropriate DNA testing for their patients and families

Demonstrate in their practice why pediatric knowledge is crucial for DNA testing

What value genetics?

Old man--cough and fever, progresses to severe respiratory distress with fatigue.

Could have gone on to ARDS, renal failure, myocardial infarction, stroke but vaccines, boost, and Paxlovid.

1.5 months later has persisting cough, difficulty with word recall and concentration (brain fog), sleep difficulties for 1 month.

Molecular technology provided RNA vaccines; ?little value genetics in ID.

Need for clinical geneticists?

- 1. A child born at 28 weeks has ongoing retinal, pulmonary, developmental problems
 - 3. Unusual facies, heart defect, hypercalcemia
- 2. A newborn declines after feeding with lethargy, anion gap



1. Prematurity

Immature CNS and muscles: global hypotonia, poor oromotor function

CNS bleeds: Cerebral palsy, seizures, hydrocephalus

Poor nutrition, enterocolitis: Malabsorption, fragile bones, combined oromotor/absorptive defects

Retinopathy, CNS problems: Visuospatial, coordination problems

Parental support: Strain on resources

Genetic contribution ill-defined:
Neonatal, Developmental, Ophthy, Neuro care
>>>> Geneticist

But don't dismiss genetics: If cannot cure, can always heal

2. Newborn Screening ACT Sheet

Elevated C3 Acylcarnitine; Propionic Acidemia and Methylmalonic Acidemia

Medical Emergency: Take the Following IMMEDIATE Actions Contact family, repeat screen if second not done.



Evaluate the newborn; check urine for ketones.

Initiate confirmatory/diagnostic testing -now often DNA.


Plasma amino acids, plasma acylcarnitine profile, and urine organic acids.


Consult with metabolic specialist. (See attached list.)


Educate family, report to newborn screening program.


Neonatologist, pediatrician to tertiary metabolic specialist >> Clinical geneticist

?Expanded screen to genomic screen










Baby girl born to 28-year-old parents with no prenatal concerns. She had some trouble breastfeeding in the nursery but mother was able to pump until 2 months of age.


- •Normal motor milestones with mild speech delay that responded to therapy
- •Epilepsy-early febrile seizures, later anticonvulsants, seizure free by teen years
- •Difficulties with reading and math but no sensory or social difficulties. Later balance of mainstream and resource classes, graduated high school but living with parents.


Hypotonia Feeding Issues Dysmorphology Delay Microarray first

















Algorithm for DNA testing and patient-parental counsel

ORDERING

- 1. Microarray first for children with dysmorphology, delays—blood sample to Dr. Tonk
- 2. DNA sequencing (one gene, panel, WES, WGS) for disorders with Mendelian inheritance—buccal swabs common.
- 3. Genome sequencing evolving, simultaneous tests standard
- 4. Be aware of OOP costs of \$2500-3500 for insured patients, Mcaid-Mcare rarely accepted.
- 5. System specialist (cardiologist, etc.) optimal to order, often have lab associations, can get costs

COUNSEL

- 1. Emphasize Ancestry, 23-Me good for relations, not disease
- 2. Look at variant prevalence--MTHFR 10-30% and bullroar
- 3. Accept variants VUS or path, state contribute to disease
- 4. Arrange parental studies for family, severity counsel

Hypermobility complex/Ehlers-Danlos syndrome








1899 patients with EDS, 905 with whole exome sequencing, 566 with potentially significant variants by clinical qualification

Must recognize autonomic imbalance as part of spectrum—POTS, IBS, increased mast cell/inflammation and altered immunity

Variant utility/contribution by clinical mechanisms: Tissue laxity + Dysautonomia (lower body blood pooling in flexible vessels decreases cerebral blood flow, with reactive adrenergic "fight-or flight" stimulation (POTS-brain fog, fatigue, tachycardia, anxiety, MCAS- asthma, rashes, hives, food-medicine intolerances),

and cholinergic suppression (IBS-bowel irregularity, reflux, nausea)

			1					P 13.1	+LIFR LIFR II	_
	*SKI Bn +AGRN		+ODC1	P 25.1	+COLO	P 16.3	+DOK7		+LIFR LIFR Jt	
36.22	*+UBE4B Nc	P 25.1	2*2+LPINI Mu	24.2	*THRB Athy	16.1	+WFS1	5		_
	*+MFN2 Np	22.3	*NLRC4 Aim	24.1	4*1+TGFBR2 Vs	4			±13.1 3*PIK3R1 Jt	
	3*3+PLOD1 Jt	22.1	+SOSI		2*SCN5A Ns		l	14.3	1*2+ADGRVI Ne	-
36.12 34.3	*ALPL Bn *DLGAP3 Nc ↑RPA2	16.7	+FSHR	1	5*2+SCN10A Ns 4*SCN11A Ns	11.2	*MYH7 Mu NEKBI Aim	23.1 23.3	3*LOX Vs 5*1+FBN2 Vs	-
34.3	*PPT1 Nm	16.3	*MAT24 Vs	22.2	CXCR6Aim	24 25-26	*+4NK2 Vs	31.3	*NR3CI Ans	-
34.2		11.2	*MA72A Vs	22.2		31.3	**************************************	31.3	*SH3TC Np	
	* <i>P3H1</i> Jt	_			4*COL7A1 Sn	32.1	+FGG	35.1	DOCK2 Aim	
21.1	*ABCA4 Ne	2	↓+IKZF2	21.31	CCRI Aim CCR5 Aim	35.2	2+F11 T1 R3 Aim	935.3	2*ADAMTS2 Jt	326
	↑+ZNF644 +AMPDI	12	*ANO6 Clot		↑14.3 *+FLNB Jt	33.4	2+FII ILRS AIII	- 35.3	2-710/10/132-31	320
1	ψ +GBA+ATPIA2	14.1	+PAX8 ILIB Aim	3	-1-14.3 -+FE/VB 30	P 12.33	+CACNB2	P 13.32	*KCNA5 Vs	
-	*HJV/HFE2 Ans	14.1	ILIRN Bn	11.2	*CPOX Apor		TC/IC/VB2	13.32	11*7+VWF Clot	EDS-rel
21.2	*+ADAMTSL4 Jt	23.3	*NEB Mu	12.2	+TFG ATP6VIA Sn	10	↓ +ANK3	13.31	*CIR Aim	LD3-IEI
	28*12+ FLG Sn	24.2	*+IFIHI Aim	21.1	+MYLK RAB7A Np	111.21	*RET Ans MAPKS Ans	11.21	+PKP2	
22	*LMNA Nm MUCI	24.3	7*4+SCN9A Ns	24	*GYG/ Mu	21.3	+EGR2 MBL2 Aim		2+GUCY2C	Genes
23.1	2*2+NTRKI Ans	31.1	+CHRNAI	25.2	*MME Np	23.2	+LDB3	12	+TRPV4	Genes
23.2	2*2+C4SO/ Mu	31.2	+TTN	26.1	+SI	24.32	2+NFKB2	12	+LRRK2	
23.3	*PPOX Apr FASLG	32.2	13°COL3AI Vs	27.1	+THPO	25.1	*COL1741 Sn	13.11	2*COL2AI Bn	A al
	2*CACNAIS Nm		16*1+COL5A2 Jt	9 29	2*OPAI Ne MUC4	25.2	+RBM20	13.12	+KMT2D	And
32.1	*+TNNT2 Mu	1	*STATI Tf-Aim			926.3	+EBF3	13.3	*MARS Np STAT2 Aim	
	3*TGFB2 Vs +LYST	35	4*2+WNT10A Sn	F 11.2	+FGFR			14.3	+IRAK3 TBK1 No	
43	3*1+RYR2 Mu	36.2	*CUL3 Ne			P 15.4	+DCHS1_IRF7_Aim	1	IFNG Aim	910
944	2*2+NLRP3 Aim	37.1	*CHRND Ans	8		15.1	*ABCC8JtM MUC5AC	23.2	+MYBPC1	310
	NLRP3 Aim	9 37.3	5*1+COL6A3 Mu	424.22	*4+TG Athy	14.3	*ANO3 Nm	9 24.31	*DNAH10 Ne OAS Aim	
$\overline{}$				/		11.2	3*5+MYBPC3 Mu	_ 1101		DNA Var
P 22.2	3*13+HFE Apor	P 15.3	IL6 Aim	P 21.3	IFNAI-IFNBI Aim		↑+F2 F2 Clot +CKAP5	P 13.2	+CHRNE	DINA Val
21.33	7*3+TNXB Jt		14 2*FKBPI4 Jt	13.3	*GNE Mu +VCP	11	The Partie Chara	13.1	3+MYH2	
21.33	3*2+COL11A2 Bn	7	14 2"FKBP14 Jt		*GNE Mu +VCP Φ+DOCK8 +SETX	12.3	*+BSCL2 Np	12	2*PMP22 Np	(Dlack Dad)
21.32	+PEX6 +APOBEC2	121.11	*CD36 Re-Clot	9	TITLANIA TSEIX	13.1	*PYGM Mu UNC93B1	11.2	*2+TNFRSF13B Aim	(Black-Red)
21.1	FOXPA Vs TEADS Vs	121.11	*CACNA2DI Nm	122.33	2*ASPN Bn	13.1	*MENI Ans POLD4 No	11.4	+NLRPI +GPIBA	(=:::::::::::::::::::::::::::::::::::::
12.3	*+PLA2G7 Aim	21.3	7*COLIA2 Bn	122.33	+COLISAI	1	*+EFEMP2 Sn +LRP5	17	+TP53 +ACADVL	
	TLAZO/AIII	22.1	+EPHB4		4*TGFBRI Vs	4 23.3	*SCN4B Vs	11/	+G6PC+CACNAIG	
6		~~	2*1+PLOD3 Jt	31.3	*IKBKAP Ans	23.3	+SCN2B	12	*SLFN14 Clot	
13	3*COL941 Bn	22.3	2+SLC26A4	32	*ALAD Apor	1	5*1+HMBS Apor	21.1	*THRA Athy	
	+KCNQ5	31.1	*FOXP2 No		*COL27A1 Bn			21.2	*JUP Vs	7
13-14	17*6+COL12A1 Mu	31.2	2+CFTR	33.2	3*GSN Ans TLR4 Vs		2*1+CACNAIH Ans	1	3*FKBP10 JtM	7
14.1	+MYO6	32.1	2*FLNC Mu	33.3	2*LMXIB Bn	1	2*PKDI Vs	21.31	*ITGA2B Clot KANSL No	1
21	3*+FIG4 No		*TNPO3 Mu	34.11	*STXBPI No	1	2*1+MEFV Aim	1	8*COL1A1 Bn	7
22.1	*+DSE Ez-Jt	34	*TBXASI Clot		+ENG +SNAPC4	P 13.3	+DNASEI	21.32	*+ITGB3 Clot	
23.3	+TNFAIP3		*2+CLCNI Mu	34.2	*+DBH Ans ABO Aim	13.13	+LITAF	23.2	2*SCN4A Mu	
25.2	*+SYNEI Mu	36.1	+PRKAG2	P 34.3	35*1+COL5A1 Jt	1	3*2+MYH11 Mu	925.3	+SEPT9	
927	+PDE10A	36.3	+DNAJB6		2*NOTCHI Vs	1	2*1+ABCC6 Jt			
						13.11	+ABCC1			
13		4 4		4 =		12.3	*UMOD Jt	P11.22	2*PIEZO2 Mu	C0
13		14	±12 *NUBPL Mt	15]	*PRRT2 Ne			60
		13.2	NFKBI Aim	12	+ATP10A	ı	*TBX6 Bn	18		
12.11	5*1+GJB2 Sn	22.1	*ATLI Ans	13.3	+TRPMI	11.2	+FUS			
		23.2	+SYNE2	15.1	3*CAPN3 Mu	11		12.1	+TTR NPCI No	genes
14.3	+ATP7B	24.1	*ACTNI Clot	21.1	2*1+DUOX2 Athy	16		1	PIK3CA Ne	Beries
		24.3	*TGFB3 Vs		*DUOXA2 Athy	12.1	4*NOD2 Aim	21.11	*TRPAI Ans	
32.1	*UGGT2 Nm		*+SPTLC2 Ans		18*4+FBNI Vs	1	+SALL1	9 22.1	+DSEL	implicated
		31.1	*TSHR Athy	21.2	*+VPS13C Ne	12.2	3*1+SLC642 Ans			Implicated
		32.12	*FBLN5 Sn	26.1	14*3+POLG Ans	13	+SLC12A3	P 22.3	*ARSF Bn	
33.3	+LIG4	32.13	*+SERPINA6 Ans		+CHD2	22.1	2*AARSI Np		ACE2 Vs TLR7 Aim	COVID19
434	2*1+F10 Clot	32.31	+DYNC1H1	926.3	+IGF1R	22.2	*ZFHX3 N°	22.2	*CLCN4 Mu +RPS6KA3	COVIDIS
		432.22	*KIF26.4 Ans			23.2	*+PKD1L2 Vs	22.13	*RSI Ne	
			*+ADSSLI Mu			23.3	3*1+PLCG2 Aim	1	*+MAP3K15 Ans	covority
P 13.3	DPP9 Mu_ICAM1 Aim					9 24.2	2*2+ZNF469 Jt	1	*CNKSR2 Ne	severity.
	+TICAMI TICAMI Aim	P11.23	1*3+RIN2 Sn					22.12	2*MBTPS2 Sn	
- 1	*NDUFAII Ne	20		21		22		22.11	*PHEX Bn \$\psi CCDC22 Nc	
	*LDLR Mu TYK2 Aim							X	↑+OTC +TIMP1 +SYN1	persisten
	3+CACNAIA	11.22	*MYH7B Mu	22.11	IFNARI-IFNAR2 Aim.	11.1	+CECRI			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13.12	*3+NOTCH3 Vs	13.32	+GNAS	9 22.3	*AIRE Aim	12.2	+NEFH	12	+EDA2R_AR Nm	(DI)
13.11	2+GDFI	9 13.33	*LAMA5 Jt		2*UBE2G2 Jt		+MORC2	13.1	*EDAI Sn	(Blue)
19			+GATA5		*COLISAI Ne	12.3	+TMPRSS6	1	2*MED12 Ne	(Diac)
			5*COL943 Bn		4°COL6.41 Mu	13.2	*TCF20 Ne		+PHKAI	
13.2	↓12 CCNEI Aim		*RTEL1 Sn		2*COL6A2 Mu	9 13.33	*2+TYMP Ans	21.1	*+ATP7A Nm	
	3*RYR/ Mu		+TNFRSF6B		TMPSS2 Aim			26.1	*BCORL1 Ne	
	+CEACAM16	Black*	EDS-one prime vari		Jt Joint		Nerve-CNS	26.2	+PHF6 CD40LG Clot	
	+SYMPK	Black +	EDS-additional vari	ant	Sn Skin		Nerve-peripheral	9 28	*IDS Jt ATP6API Sn	-
13.33	+TRPM4 IRF3 Aim	Red*+	EDS-many variants		Bn Bone		Neuromuscular	ı	*MTM1 Mu ZNF275 Ans	_
913.42	3*4+NLRP12 Aim	Blue	COVID-related gene		Mu Muscle		Autonomic-neurosensory	I	*SLC6.48 Ans	_
13.42	+TNNI3 PPP1R15A	Green	EDS-mitochondrial	function	Vs Cardiovascular		Autonomic-	I	*+LICAM No	_
13.42					Clot Coagulation		Autonomic-porphyria	1	3*4+FLNA Jt	
13.42										
13.42					Ns Neurosensory-p	ain Athy	Autonomic-thyroid	V		1



Comparison "long COVID19" or PACS and EDS dysautonomia symptoms											
	Long COVID19 1.2:1 M:F			DS M:F	COVID	EDS					
Finding	Range %	Mean %	Mean %	Range %	genes SAME	SAME					
Brain fog-confusion	3070	55	75	2789	F2	F2					
Chronic fatigue	3060	52	79	3891	LIFR	LIFR					
Dyspnea-asthma	2052	37	40	3252	NLRP3	NLRP3					
Anxiety	1240	35	60	4872	TICAM1	TICAM1					
Sleep difficulty	2035	33	56	4568	SIMILAR	SIMILAR					
Tachycardia	2048	32	71	5486	DOCK2	DOCK8					
Difficulty walking	1755	25	50	3572	FOXP4	FOXP2					
IBS symptoms	1478	22	75	6789	IRF3/IRF7	IF1H1					
Muscle weakness	1525	20	31	2249	MAPK8	MAP3K15					
Muscle aches	1222	19	54	4179	NFKB1	NFKB1A/B2					
Arthralgia/arthritis	1527	17	47	3294	PIK3CA	PIK3R1					
Syncope	014	13	39	2452	SLCA19	SLC6A2/8					
Dizziness-vertigo	1050	10	85	3989	STAT1	STAT2					
Transient rashes	720	8	41	1445	TMPRSS2	TMPRSS6					
Headache	217	8	72	5578	ZNF 275	ZNF469/644					

Common conditions involve multigene networks, DNA changes (mutations) contributors rather than diagnoses.

Gene repair-replacement limited, engineered therapies (Gleevec etc.) powerful and proliferating

Cell-free DNA in maternal or cancer patient bloodstreams one of the ongoing insights from DNA technology

Era of pediatrician and pediatric specialist plus laboratory, not clinical genetics

Era of single gene disorders giving way to genomic technologies that show gene networks, the "rest of the story" that explains incomplete penetrance, variable expressivity and disease severity

NextGen genetics is of value, consider genetic influence even in environmental disorders with severe or unusual outcomes.

"The capacity to blunder slightly is the real marvel of DNA. Without this special attribute, we would still be anaerobic bacteria and there would be no music."

Lewis Thomas MD

golder.wilson@ttuhsc.edu

Covenant-sponsored clinic second Monday-Tuesday Scheduling ph 806-743-7334 fax -7332 Currently chromosomes-microarray through Dr. Tonk